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The modulation of synaptic plasticity by NMDA receptor (NMDAR)-mediated processes is essential for many forms of learning and 
memory. Activation of NMDARs by glutamate requires the binding of a coagonist to a regulatory site of the receptor. In many forebrain 
regions, this coagonist is D-serine. Here, we show that experimental epilepsy in rats is associated with a reduction in the CNS levels of 
D-serine, which leads to a desaturation of the coagonist binding site of synaptic and extrasynaptic NMDARs. In addition, the subunit 
composition of synaptic NMDARs changes in chronic epilepsy. The desaturation of NMDARs causes a deficit in hippocampal long-term 
potentiation, which can be rescued with exogenously supplied D-serine. Importantly, exogenous D-serine improves spatial learning in 
epileptic animals. These results strongly suggest that D-serine deficiency is important in the amnestic symptoms of temporal lobe 
epilepsy. Our results point to a possible clinical utility of D-serine to alleviate these disease manifestations. 
Introduction 
N M D A receptors (NMDARs) are of central importance in excit-
atory synaptic transmission. The activation of these receptors by 
synaptically released glutamate is required for different forms of 
synaptic long-term plasticity in the brain, and is thought to be 
important for intact learning and memory processes. However, 
full activation of the N M D A R complex requires not only binding 
of the agonist glutamate but also binding of either D-serine or 
glycine to an allosteric coagonist binding site (Johnson and As-
cher, 1987; Kemp and Leeson, 1993). This has led to the idea that 
coagonist binding to the N M D A R complex modulates the induc-
tion of NMDAR-dependent synaptic plasticity. Indeed, applying 
antagonists for the N M D A R coagonist binding site blocks induc¬
tion of long-term potentiation (LTP) both in vivo (Mizutani et 
al., 1991; Thiels et al., 1992) and in vitro (Bashir et al., 1990; Yang 
et al., 2003). More importantly, decreasing the levels of endoge-
nously released D-serine by application of the D-serine degrading 
enzyme D-amino acid oxidase (DAO) suppressed N M D A R activ-
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ity and the induction of LTP in cell culture, as well as to a lesser 
extent in acute hippocampal slices (Yang et al., 2003). Indeed, 
several studies revealed that D-serine is released from astroglia in 
aCa 2 +-dependent manner and regulates activation of NMDARs 
(Schell et al., 1995; Mothet et al., 2000; Yang et al., 2003; Panatier 
et al., 2006). A study has shown that, in intact brain tissue, astro-
cytes control the levels of D-serine within the domain they oc-
cupy. Their D-serine release appears to be controlled by neuronal 
and astrocytic activity and modulates NMDARs and LTP (Hen-
neberger et al., 2010). Recently, experiments using selective de¬
grading enzymes for D-serine and glycine have revealed that 
D-serine modulates synaptic NMDARs, whereas glycine gates ex-
trasynaptic NMDARs, matching the preferential affinity of syn-
aptic and extrasynaptic NMDARs for D-serine and glycine, 
respectively (Fossat et al., 2012; Papouin et al., 2012). Further-
more, NMDAR-dependent synaptic plasticity in the normal hip-
pocampus seems to require synaptic NMDARs only (Fossat et al., 
2012; Papouin et al., 2012). These studies collectively suggest that 
precisely controlled D-serine release from individual astrocytes 
gates synaptic NMDARs, thereby controlling synaptic plasticity. 
The central importance of D-serine-mediated cotransmission 
begs the question whether D-serine levels in the brain might be 
altered in neurological disorders. Indeed, several studies have 
shown that CSF and serum levels of D-serine are reduced in pa-
tients wi th schizophrenia (Hashimoto et al., 2003). Moreover, 
genetic variants in the genes encoding the major enzyme synthe¬
sizing D-serine, serine racemase (Srr), and the D-serine degrading 
enzyme DAO have been shown to be associated wi th schizophre¬
nia or schizophrenia-like symptoms in mice (Labrie et al., 2009, 
2010; for review, see Boks et al., 2007). However, how NMDAR 
cotransmission, and as a consequence N M D A R function and 
synaptic plasticity, is altered is not known for any neurological 
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disorders. Temporal lobe epilepsy is associated wi th manifold 
cognitive changes, but their underlying mechanisms are un-
known. Here, we show that D-serine levels are reduced in exper-
imental temporal lobe epilepsy, causing desaturation of synaptic 
and extrasynaptic NMDARs and thereby deficits in hippocampal 
LTP. Exogenous D-serine rescues hippocampal LTP and amelio¬
rates behavioral deficits in epileptic animals. 
Materials and Methods 
Pilocarpine-induced temporal lobe epilepsy. A sustained status epilepticus 
(SE) was induced in young adult male Wistar rats (—30 d, 140-150 g; 
Charles River) by administration of the muscarinic agonist pilocarpine 
according to protocols described previously (Turski et al., 1983; Caval-
heiro et al., 1987). Methyl scopolamine nitrate (1 mg/kg, i.p. or s.c.; 
Sigma) was preapplied 30 m i n before pilocarpine injection to reduce 
peripheral cholinergic effects. Then animals of the experimental group 
received pilocarpine hydrochloride, freshly dissolved in 0.9% saline (340 
mg/kg, i.p. or s.c.; Sigma). Control rats received the same dose of methyl 
scopolamine nitrate and 30 m i n later sterile saline. In most rats, SE de-
veloped within 30-60 m i n and was stopped after 40 m i n by application 
of diazepam (4mg/kg, i.p. or s.c.), which was occasionally repeated when 
necessary. The remaining animals received a second injection of pilo-
carpine after 60 min (170 mg/kg, i.p. or s.c.). Overall, 60-90% of treated 
animals developed SE. After recovery of 7-10 d, rats were monitored for 
2-6 weeks (8 h/d) to observe behavioral limbic seizures. Only rats expe¬
riencing more than three seizures were included in this study. Control 
rats were held in the same observation facility to exclude housing effects. 
Experiments were performed at the age of 50-100 d (300-500 g). A l l 
animal experiments were done in accordance wi th institutional and na¬
tional guidelines for animal welfare. 
Total RNA preparation and RT-PCR. Rat brain tissues f rom pilo-
carpine and control rats were rapidly dissected, snap frozen in isopen-
tane, and stored at — 80°C. Total RNA was prepared by the Trizol method 
(Invitrogen). Five micrograms of RNA and 0.5 jug oligo-dT(20) primers 
(Invitrogen) were heated at 70°C for 4 m i n , chilled on ice, and reverse 
transcribed in a total volume of 20 jul containing 4 jul first-strand buffer 
(Invitrogen), 2 ju lo f0 .1 M DTT, 1 u d o f 1 0 m M dNTPs, 0.5 jul of RNase 
OUT (Invitrogen), and 200 U of Superscript II reverse transcriptase (In-
vitrogen) at 42°C for 50 min. 
Taqman analyses. RT-qPCR was performed using an ABI 7900 sequence 
detector (PerkinElmer Life and Analytical Sciences) on cDNA samples, at 
50°C for 2 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 s, and 
then 60°C for 1 min using the Universal PCR Master M i x (PerkinElmer Life 
and Analytical Sciences). Taqman primer and probe sets were from Applied 
Biosystems: Rn01648369_m1 for Srr, Rn01480801_m1 for DAO, 
Rn00586891_m1 for sodium-independent alanine-serine-cysteine 
transporter 1 (Asc-1), and Rn01528258_m1 synaptophysin. Synaptophy-
sin was used to normalize for the amount of sample in a given reaction (Chen 
et al., 2001). Results are expressed as relative expression to the control gene 
(ACt) . 
HPLC analyses. Tissue samples were homogenized in 10 vol o f 5% 
trichloroacetic acid (TCA), and the homogenates were centrifuged at 
18,000 X g at 4 °C for 30 min . To remove TCA, the supernatants were 
washed three times wi th water-saturated diethyl ether. The resultant 
samples were used for HPLC analysis. Amino acid enantiomers were 
separated by HPLC using a carbon 18 reverse-phase column (250 m m ) 
(Knauer; Advanced Scientific Instruments) wi th fluorimetric detection 
after derivatization w i t h N-isobutyryl-L-cysteine and o-phthalaldehyde 
(OPA). The N-isobutyryl-L-cysteine/OPA derivatives were immediately 
applied to the HPLC system (Knauer; Advanced Scientific Instruments). 
Mobile phase was 11% MeCN in 0.1 M sodium acetate buffer, pH 6.0. 
Amino acids were separated isocratically for 37 m i n , and then the column 
was eluted wi th 50% H 2 O/50% MeCN for 5 min . After that, the column 
was re-equilibrated for 15 m i n under the initial conditions. The flow 
rate was 0.125 ml /min . Fluorescence detection of each amino acid deriv¬
ative was performed at 443 nm w i t h excitation at 344 nm according to 
Grant et al., 2006. We calculated the D-serine ratio compared w i t h total 
serine content [D-serine/(D-serine + L-serine)] according to Hikidaetal . , 
2008 to minimize variability. From each chromatogram, D-serine ratio 
compared w i t h total serine was calculated. 
Protein extraction and Western blot. Hippocampal samples f rom 
pilocarpine-treated and control rats were extracted and snap frozen in 
l iquid nitrogen. Protein extracts were generated using ultrasonication in 
RIPA buffer (10 mM Tris-HCl, pH 8, 150 mM NaCl, 5 mM EDTA, 1% 
NP-40, 0.5% sodium deoxycholate, and 0 .1% SDS) and protease inhib-
itors. After centrifugation, 15 jug of supernatant was used for Western 
blot analysis. Protein concentration was determined using the BCAPro-
tein Assay (Pierce). The Western blot was conducted using NuPAGE 
4 -12% Bis-Tris gels from Invitrogen. After blotting, the membranes 
were blocked wi th 5% milky powder overnight and immunostained with 
a rabbit-derived serine racemase antibody (ab45543, 1:500, 2 h; Abcam) 
and enhanced chemiluminescence (Pierce) followed by goat a-rabbit 
heavy/light (H/L) peroxidase (1:3000, 1 h; The Jackson Laboratory). Af¬
ter stripping, the blot was labeled w i t h a rabbit-derived synaptophysin 
antibody (ab52636, 1:5000, 2 h; Abcam) as a reference and enhanced 
chemiluminescence (Pierce), followed by goat a-rabbit H/L peroxidase 
development (1:3000, 1 h; The Jackson Laboratory). The blots were an¬
alyzed using the ChemiDoc MP Imagine System from Bio-Rad and the 
ImageLab 4.01 software. 
Slice preparation. For LTP experiments, animals were deeply anesthe¬
tized w i t h diethylether and decapitated, and the brains were dissected out 
quickly. Transversal hippocampal slices (400 jum) were prepared using a 
vibratome (Leica 1000S; Integraslice 7550 mm from Campden Instru-
ments) in ice-cold dissection f luid containing the following ( in m M ) : 125 
NaCl, 25 NaHCO 3 , 3 KCl, 1.25 NaH 2 PO 4 , 0.2 CaCl 2 , 5 MgSO 4 , and 13 
D-glucose. A l l procedures were performed according to the guidelines 
laid down by the Animal Care and Use Committees at the Universities of 
Bonn and Rostock, respectively. Slices were then transferred into an 
interface chamber heated within 30-40 m i n f rom room temperature to 
35°C and superfused (1.8 -2.0 ml /min) wi th bath solution containing the 
following ( in m M ) : 125 NaCl, 26 NaHCO 3 , 3 KCl , 1.25 NaH 2 PO 4 , 2.5 
CaCl 2 , 1.3 M g C l 2 , and 13 D-glucose. This solution was continuously 
bubbled wi th carbogen (95% O 2 , 5 % C O 2 ) to maintain the pH of 7.4. 
Sucrose was used to adjust the osmolality to 306-308 mOsm/kg. Slices 
were allowed to recover at least 60 m i n before recordings were per¬
formed. For patch-clamp recordings, rats were deeply anesthetized with 
a mixture of 0.7 ml of Ketavet injection solution and 0.3 ml of Rompun 
solution injected into the abdomen of the rat. To achieve rapid cooling of 
brain tissue already during preparation, which maximizes cell preserva¬
tion, heart perfusion was performed w i t h ice-cold ACSF slicing solution 
containing the following ( in m M ) : 125 NaCl, 25 NaHCO 3 , 3 KCl , 1.25 
NaH 2 PO 4 , 0.2 CaCl 2 , 5 MgSO 4 , and 13 D-glucose (306 mOsm osmolal-
ity). Hippocampal slices (300 jum) were obtained w i t h a vibratome ( M i -
crom HM 650V) in the same solution and transferred to ACSF 
containing the following (in m M ) : 125 NaCl, 3.5 KCl, 1.25 NaH 2 PO 4 , 26 
NaHCO 3 , 2 CaCl 2,2.5 M g C l 2 , and 15 D-glucose (306 mOsm osmolality). 
Brain slice were then incubated at 35°C for 35 m i n and were allowed to 
recover at least 60 m i n before recordings were performed. Al l solutions 
were continuously bubbled wi th 95% O 2 /5%CO 2 . 
Field EPSP recording. Lateral (LPP) and medial (MPP) perforant path 
fibers were selectively and alternately stimulated at a frequency of0.033 
Hz via two bipolar platinum wire electrodes (0.1-0.3 mA, 100 us, paired-
pulse stimulation, 40 ms apart) placed in both the outer (OML) and 
middle ( M M L ) molecular layers of the dentate gyrus (DG). Field EPSPs 
(fEPSPs) were simultaneously recorded in the O M L and M M L via glass 
pipettes (borosilicate glass capillaries, —4-6 M f t ) filled wi th bath solu-
t ion. A l l recordings were performed at 35°C. The stimulation strength 
was adjusted to yield half-maximal fEPSP amplitudes. LTP was induced 
by high-frequency patterned stimulation (10 trains of 20 impulses at 100 Hz, 
1 s apart). Analog data were digitized (Digidata 1322 from Molecular De¬
vices; Micro1401 from Cambridge Electronic Design) and stored for offline 
analysis (pClamp software from Molecular Devices; Signal2 from Cam¬
bridge Electronic Design). The group I I I metabotropic glutamate receptor 
agonist L-2-amino-4-phosphonobutyrate ( L - A P - 4 ) was obtained from Toc-
ris Cookson. Al l other chemicals were purchased from Sigma. 
LPP stimulation evoked negative fEPSPs in the O M L and large posi-
tivities in the M M L . In contrast, MPP stimulation resulted in negative 
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M M L potentials and O M L positivities as described previously (Dietrich 
etal. , 1997). 
Patch-clamp recordings. Slices (300 / t i n ) were placed in a submerged 
chamber on the stage of an upright microscope (Carl Zeiss Axioskop) 
and superfused wi th ACSF containing the following ( in m M ) : 125 NaCl, 
3.5 KCl , 1.25 NaH 2 PO 4 , 26 NaHCO 3 , 2 CaCl 2 , and 15 D-glucose. M i -
cropipettes were fabricated with a Flaming/Brown-type micropipette 
puller (model P-97, 3-5 M f t ; Sutter Instruments) and filled w i t h intra­
cellular solution containing the following (in m M ) : 100 CsMS, 20 TEA-
Cl, 0.05 CaCl 2 , 10 HEPES acid, 0.5 EGTA, 2 Mg-ATP, and 1 Na 2-ATP. 
Whole-cell recordings were obtained from visually identified granule 
cells using either an Axopatch 200B or a Multiclamp 700B amplifier 
(Molecular Devices). To improve the voltage control, capacitance and 
series resistance was compensated (50-70%). Current signals were sam­
pled at 10 kHz, digitized, and stored on hard disk for later analysis using 
the pClamp9 acquisition software (Molecular Devices). A glass stimula­
t ion electrode filled wi th ACSF wi th a tip diameter of ~ 7 / t i n was posi­
tioned in the O M L of the DG for LPP stimulation. 
Behavioral analyses. Learning behavior was tested using the hidden 
platform task in the Morris water maze (110 cm maze diameter and 50 
cm water depth, 15 cm platform diameter located 25 cm from the maze 
r im, four large black-and-white cues). For habituation purposes, all an­
imals were allowed to explore the water maze without platform on the 
day before the experiments started (day 0, two trials for 60 s each). On day 
1, the platform was inserted 1-2 cm below the water level within a ran¬
domly chosen quadrant. From day 1 through day 7, each animal was 
allowed six consecutive trials to reach the platform from one of eight 
random, evenly spaced starting points at the water maze r im. When the 
animal failed to reach the platform within 60 s, it was manually placed on 
the platform. Regardless of whether the animal had located the platform 
or not, the animal was allowed to stay for another 30 s on the platform, 
before it was placed back into its cage. After 60 s recovering time in the 
cage, the next trial was started. On the final day of the experiment (i.e., 
day 8), a probe trial was performed in which the platform was omitted 
and the animals were allowed to swim for 60 s. Animal location was tracked 
using the Ethovision Color software (Noldus). A subgroup of animals was 
orally treated with D-serine. To this end, each animal was given an individual 
D-serine dosage in the drinking water. First, the drinking volume and the 
body weight were recorded daily during a baseline phase of 1 week. Based on 
these values, the individual D-serine content in the drinking water was cal¬
culated to reach 32 mg/kg body weight. During the treatment phase, the 
drinking volume and the body weight were recorded every 2-3 d to adjust 
the D-serine content in the drinking water. After 1 week of D-serine supply, 
the behavioral experiments were started, and the D-serine treatment was 
further maintained. After completing the Morr i s water maze learning 
tasks, all animals were decapitated under anesthesia, and the hip¬
pocampi were dissected and subsequently frozen in l i q u i d nitrogen 
for HPLC-based D-serine measurements. 
Seizure frequency analyses. Rats were video monitored for at least five 
12-hour periods on consecutive days for the occurrence of spontaneous 
seizures. Al l spontaneous seizures were classified as follows: stage I, immo¬
bility, rigid posture; stage I I , facial clonic movements, head bobbing; stage 
I I I , additional clonus of the forelimbs; stage IV, severe seizures with rearing; 
and stage V, severe seizures with rearing and falling/loss of righting ability. 
Data analyses and statistics. Data analysis was performed in Igor anal¬
ysis software. A mathematical f it function of the following form was used 
to define kinetic parameters of the recorded EPSCs: 
/ / ( t - t o f f ) \ \ 2 / ( t - t p f ) \ 
f(t) = A 1 I 1 - Л ta1 )\ X Л tq ) 
I / ( t - t o f f ) \ \ 2 / ( t - t o f ) \ 
+ A 2 I 1 - Л ta2 )\ X Л tt2 ) + y o f f . 
The rise time was determined by the slope between the data points at 20 
and 80% ofthe maximal EPSC amplitude. The time course from the data 
pointat80%ofEPSCamplitudevalueafterEPSC maximum unti l 10%of 
the amplitude value were reached described the decay of the EPSC. Half-
width was defined as the width of the EPSC (in milliseconds) at the 
half-maximal amplitude value. N M D A / A M P A ratios were determined 
by dividing the average o f five consecutive baseline N M D A EPSCs by the 
average of five consecutive baseline A M P D A EPSCs. The N M D A / A M P A 
ratio of 16 cells was used to calculate a reasonable average of the per¬
formed EPSC recordings. The success rate of LTP induction was quanti­
tatively analyzed by setting a threshold of > 5 % potentiation a f t e r 1 h o f 
post-tetanus recording over the baseline values. 
A l l data are expressed as the mean ± SEM. Effects within one group 
were tested using the paired Student's t test. Differences in the effects 
between groups were tested using the nonparametric Mann-Whitney 
test, unpaired Student's t test, or A N O V A as indicated. p values <0.05 
were considered statistically significant and marked wi th a single asterisk, 
whereas p values <0.01 were marked w i t h two asterisks. 
Results 
Altered synaptic NMDAR-mediated EPSCs in 
epileptic animals 
We first studied the properties of synaptic NMDARs in control 
and epileptic animals at LPP synapses formed onto hippocampal 
dentate granule neurons, which are easily discriminated based on 
morphological and functional criteria (see Materials and Meth¬
ods). The NMDA-mediated component of LPP EPSCs was iso¬
lated from the total glutamatergic EPSC by application of 10 JUM 
CNQX (Fig. 1A, black and dark gray traces). The additional ap­
plication of 25 J U M D - A P V completely abolished the EPSC (Fig. 
1 A, light gray traces). There was no significant difference in the 
NMDA/AMPA ratio when comparing control and chronically 
epileptic animals (sham, 0.29 ± 0.05 and post-SE, 0.22 ± 0.05, 
n = 8 for both groups; p = 0.68). However, the kinetics of the 
pharmacologically isolated N M D A EPSCs appeared substantially 
slower in epileptic rats (Fig. 1B, black traces indicate control, gray 
traces indicate SE). Indeed, the time course of activation, as well 
as the decay time course were slowed and the half-width in¬
c r e a s e d ( F i g . ^ p ha l f -width = 0 . 0 0 3 , p decay = 0 . 0 3 , p r i se time = 0 . 0 1 , 
n = 16 for both groups, unpaired t test). To confirm the identity 
of LPP EPSCs, the paired-pulse ratio of the responses was deter¬
mined (two stimulations, 40 ms apart, paired pulse ratio defined 
as the ratio ofthe second amplitude to the first) and found to be 
1.4 ± 0.05 for N M D A and 1.2 ± 0.07 for AMPA EPSCs, as ex­
pected for LPP responses (Dietrich et al. 1997). Application of 
L - A P - 4 similarly reduced the NMDAR-mediated EPSCs in both 
control and epileptic animals (by 32 ± 6 and 34 ± 7%, respec­
tively, n = 6 for both groups, Mann-Whitney test, p = 0.90), 
similar to values described previously (Dietrich et al. 1997). 
Input-output curves of N M D A EPSCs in control and epileptic 
animals showed a significant difference in the maximal EPSC ampli¬
tude (sham, -261 ± 26 pA, n = 6;post-SE, 141 ± 22 pA, n = 9,p = 
0.009, unpaired t test of the maximum of a sigmoidal curve fitted to 
the data points; Fig. 1D), whereas the stimulation intensity required 
for the half-maximal EPSC amplitude is not significantly different 
between the two groups (sham, 0.60 ± 0.03 mA, n = 6; post-SE, 
0.81 ± 0.09 mA, n = 9, p = 0.13). This suggests a reduction in 
NMDAR-mediated synaptic currents in epileptic animals. 
The slowing of NMDAR kinetics might indicate altered subunit 
composition, i.e., as a result of a higher contribution of NR2B-
containing receptors in chronic epilepsy. Therefore, we recorded 
synaptic N M D A EPSCs and applied the NR2A, NR2B, and NR2C/D 
selective antagonists NVP-AAM007 ([(R)-[(S)-1-(4-bromo-
phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-
yl)-methyl]phosphonic acid), Ro25-6981 [R-(R,S)-a-(4-hydroxy-
phenyl)-^-methyl-4-(phenylmethyl)-1-piperidine propranol], and 
PPDA [(2S*, 3R*)-1-(phenanthren-2-carbonyl)piperazine-2,3-
dicarboxylic acid], respectively (Fig. 2A-C) . In control animals, 
Ro25-6981 (0.5 JUM) reduced N M D A EPSCs by 17 ± 5% (paired t 
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Figure 1. Altered synaptic NMDAR-mediated EPSCs in epileptic animals. A, Representative 
synaptic EPSCs in sham-control and epileptic (post-SE) animals at LPP synapses in ACSF, fol-
lowed by application of 10 JUM CNQX (gray) and additional application of 25 JUMD-APV (light 
gray). B, Representative NMDA EPSCs showing the slower kinetics in epileptic rats. C, Quantifi-
cation of the decay time course (decay time constant r d e c a y ) , the half-width, and the 20 - 80% 
rise time of NMDA EPSCs. D, Input- output curve of NMDA EPSCs in sham-control (open 
symbols) and epileptic animals (filled symbols), stimulating the LPP and recording from 
DGCs. Lines represent average curves of the two groups fitted with sigmoidal functions. 
*p < 0.05, * *p < 0.01. 
test, p = 0.020, n = 12; Fig. 2A). PPDA (1 JUM; Fig. 2A) and NVP-
AAM077 (50 nM; Fig. 2C) also caused a significant reduction of the 
N M D A EPSCs by 27 ± 5% (paired t test p = 0.003, n = 8) or 22 ± 
3% (paired ttestp = 0.008, n = 6), respectively (summary in Fig. 2D, 
white bars). In pilocarpine-treated animals, Ro25-6981 reduced 
N M D A EPSCs by 39 ± 4% (paired t test p = 0.009, n = 9; Fig. 2B), 
whereas PPDA did not cause significant reductions (by 10 ± 5%, 
paired t test, p = 0.08, n = 7). The difference between the fractions 
blocked by Ro25-6981 and PPDA in control and epileptic animals 
was significant (Fig. 2D, §p = 0.046 and §§p = 0.005, M a n n -
Whitney test). The application of the NR2A-preferring blocker 
NVP-AAM077 caused blocking effects similar to those in control 
animals (31 ± 5%, paired ttest, p = 0.001, n = 6; Fig. 2C, summary 
in D). These data demonstrate an increase in the proportion of syn-
aptic NR2B-containing receptors in chronic epilepsy, with a con¬
comitant decrease in NR2C/D-containing receptors. 
Reduction of the NMDAR coagonist D-serine in 
chronic epilepsy 
The properties of synaptic NMDARs are powerfully modulated 
by the endogenous coagonist D-serine (Fossat et al., 2012; Pap-
ouin et al., 2012). To examine whether a reduction in D-serine 
content of the hippocampus could contribute to reduced N M D A 
EPSCs (Fig. 1D), we examined the ratio of D-serine/L-serine in the 
hippocampus of normal and epileptic rats. Using HPLC, we 
found that the D-serine/L-serine ratios are significantly reduced in 
the hippocampus of epileptic rats (Fig. 3A; two-way ANOVA 
treatment effect, F ( 1 2 2 ) = 16.30, p = 0.0006; brain region effect, 
two-way ANOVA, F ( 1 2 2 ) = 4.51, p = 0.0451; no interaction), 
consistent with a reduction of hippocampal D-serine levels. We 
then examined whether pilocarpine treatment of rats affects the 
expression of genes involved in generation (Srr), degradation 
(DAO), or transport (Asc-1) of D-serine using quantitative real¬
time RT-PCR. We analyzed gene expression in different hip-
pocampal subfields and the cerebral cortex. The expression of 
serine racemase was unaffected by SE in DG, with a small but 
significant downregulation in the CA1 subfield (Fig. 3 B, p = 
0.0344). In contrast, the expression of the enzyme DAO was sig¬
nificantly elevated in all subfields of the hippocampus and the 
cerebral cortex (Fig. 3C; CA1, p = 0.0007; CA3, p = 0.0001; DG, 
p = 0.0202; cerebral cortex, p = 0.0246, Mann-Whitney test), 
but it should be noted that the levels of expression overall were 
low. The expression of the high-affinity D- and L-serine trans¬
porter Asc-1, which is localized in dendrites and somata of neu-
rons and clears D-serine from synaptic sites, was unaltered in CA3 
and DG, with a significant downregulation only in the CA1 re¬
gion (Fig. 3D; CA1, p = 0.0025, Mann-Whitney test). We inves¬
tigated whether the observed changes in Srr and DAO mRNA 
result in altered hippocampal protein levels. For Srr, Western blot 
analyses revealed a significant reduction of relative Srr protein 
levels normalized to synaptophysin levels in whole hippocampal 
homogenates (Fig. 3E; sham, 0.28 ± 0.007, n = 6; post-SE, 0.21 ± 
0.02, n = 6, p = 0.0043, Mann-Whitney test). DAO protein levels 
were undetectable using Western blots in our hands. 
Together, these results show that hippocampal D-serine levels 
are reduced in chronic epilepsy and suggest that this may be 
attributable to changes in the enzymes that synthesize and de¬
grade D-serine. 
Decreased occupancy of the glycine-binding site of 
synaptic NMDARs 
Decreased levels of D-serine predict that a decreased occupancy of 
the coagonist binding site might contribute to the reduction of syn-
aptic N M D A currents in pilocarpine-treated animals. We examined 
this hypothesis by applying saturating concentrations of 10 JUM 
D-serine after baseline N M D A EPSC recording (Fig. 4A, B). We 
stimulated either with a single stimulation (open symbols) or burst 
stimulation (five stimuli at 100 Hz; Fig. 4A,B, filled symbols). Ap-
plication of D-serine caused a significant increase of single and burst 
stimulation-evoked N M D A EPSC amplitudes in both control and 
epileptic animals (Fig. 4C; single, p = 0.0002; burst, p = 0.002; D, 
single,p = 0.003; burst,p = 0.004, ttest). However, the magnitude of 
the D-serine-mediated increase in N M D A EPSCs was larger in 
pilocarpine-treated animals compared with sham animals for both 
single and burst stimulation (summary in Fig. 4E; single stimulation: 
increase by 47 ± 7%, n = 8 and 88 ± 19%, n = 9, in control and 
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Figure2. Altered subunit composition of NMDARs. ExaminationofNMDARsubunitcomposition using theNR2A-,NR2B-,and NR2C/D-specificantagonistsNVP-AAM007 (50 nM),Ro25-6981 
(0.5 JUM), and PPDA (1 JUM), respectively. A and B show representative experiments with consecutive application of Ro25-6981 and PPDA in sham-control (A) and epileptic animals (B). C, 
Experiments, either with application of NVP-AAM007 (top traces) or Ro25-6981 (middle traces) in sham-control and epileptic animals. Also in these experiments, subsequent application of D-APV 
blocked the EPSC completely (bottom traces). D, Quantification of the fraction of the NMDA peak EPSC blocked by the varioussubtype-selective antagonists in sham-control and epileptic rats. These 
data demonstrate an increase in the proportion of synaptic NR2B-containing receptors in chronic epilepsy. Error bars represent SEM.*p < 0.05, * *p < 0.01, §p = 0.046, §§p = 0.005. 
epileptic tissue, respectively,p = 0.026; burst stimulation: increase of 
N M D A EPSCs by 65 ± 12%, n = 8 and 134 ± 31%, n = 9 for control 
and epileptic animals, respectively, p = 0.04, Mann-Whitney test). 
The charge transferred during N M D A EPSCs was similarly aug¬
mented for single and burst stimulation in sham and epileptic ani¬
mals (Fig. 4 F, G), with a significantly larger increase observed for the 
epileptic animals (summary in Fig. 4H). This suggests that the de-
creased D-serine levels in the epileptic brain cause a decrease in the 
occupancy of the coagonist binding site of synaptic NMDARs, re¬
sulting in reduced NMDAR-mediated currents and charge transfer. 
In these experiments, we frequently observed a prominent sustained 
inward current after burst stimulation, in particular in epileptic an¬
imals after D-serine application (Fig. 47). We quantified the sus¬
tained inward current 217-222 ms after the onset of the synaptic 
burst stimulation (Fig. 47, gray markers) and found that it is signifi-
cantly augmented by D-serine in control and epileptic animals (p = 
0.03 and 0.008, respectively, paired t test; Fig. 4/). In epilepsy, the 
augmentation was significantly larger ( p = 0.003, Mann-Whitney 
test; Fig. 477). 
Effects of D-serine on perisynaptic NMDARs in control and 
epileptic animals 
This effect could be explained by activation of extrasynaptic 
NMDARs (Lozovaya et al., 2004), which can be activated by spill-
over of synaptically released glutamate during bursts of high-
frequency activity (Kullmann and Asztely, 1998). Therefore, we 
addressed more directly whether there are epilepsy-associated 
changes in these receptors and whether the saturation of their 
coagonist binding site changes. To isolate the contribution of 
perisynaptic receptors, we evoked N M D A EPSCs wi th either sin¬
gle or burst stimulation (either a single stimulus or five stimula¬
tions at 100 Hz, repeated every 10 s; example traces in Fig. 5A 
indicated wi th 1). Application of the use-dependent blocker MK-
801 while stimulating with a single stimulus caused a progressive 
and irreversible block of the resulting synaptic N M D A re-
sponses (Fig. 5B). After washout of MK-801 , burst stimulation 
was initiated and evoked a small compound N M D A EPSC 
(Fig. 5A, example traces indicated w i t h 2, B). This compound 
N M D A EPSC was attributable to the recruitment of perisyn-
aptic NMDARs remained unblocked by MK-801 ( — 16.5 ± 1.3 
pA, n = 6). As for synaptic NMDARs, we tested whether the 
coagonist binding sites ofperisynaptic NMDARs are saturated 
or not. We added 10 JUM exogenous D-serine, which did not 
significantly increase the magnitude of perisynaptic N M D A 
EPSCs (change by 16 ± 18%, p = 0.4, paired t test, n = 6; Fig. 
5B, D-serine application shown at higher magnification in in¬
set), implying that the coagonist binding sites of perisynaptic 
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Figure 3. Reduction ofthe NMDAR coagonist D-serine in chronic epilepsy. A, Analysis ofthe 
D-serine content in the hippocampus of normal and epileptic rats using HPLC (see Materials and 
Methods). Levelsof D-serine are significantly reduced in the hippocampus of epileptic rats. B-D, 
Quantitative real-time RT-PCR quantification of the expression of Srr (B), DAO (0, and the 
amino acid transporter Asc-1 (D), which transports D-serine, in different hippocampal subfields 
and the cerebral cortex as indicated. Relative expression units using synaptophysin as control 
gene were calculated (ДО). Note the downregulation of Srr in the CA1 subfield, as well as the 
significantly elevated expression of DAO in all subfields ofthe hippocampus and the cerebral 
cortex (*p < 0.05, **p < 0 . 0 1 , < 0.001). E, Western blot analyses of theSrr hippocampal 
protein levels normalized to synaptophysin (Sph) levels in whole hippocampal homogenates. 
Levels of Srr are significantly reduced in epileptic animals. 
NMDARs are saturated under our recording conditions in 
control animals. In epileptic animals, a compound perisynap-
tic EPSC to burst stimulation could also be elicited after block­
ing synaptic NMDARs (— 22.5 ± 5.5 pA, n = 6; example traces 
in Fig. 5D indicated w i t h 2, E). The magnitude of perisynaptic 
EPSCs was not different when comparing control and 
pilocarpine-treated animals. However, the application of 
D-serine caused a potent increase in the magnitude of the 
perisynaptic EPSC in epileptic rats by 67.5 ± 13.0% (paired t 
test, p = 0.0004; example traces in Fig. 5D indicated w i t h 2 and 
3, D-serine applications shown at higher magnification in in¬
set). The potentiation of perisynaptic N M D A EPSCs was sig¬
nificantly greater in pilocarpine-treated compared w i t h 
control animals (Fig. 5E; Mann-Whitney test, p = 0.02). Ad¬
ditionally, the perisynaptic EPSCs in the presence ofD-serine, 
expressed as fraction of the synaptic EPSC, was significantly 
larger in epileptic animals (perisynaptic EPSC, 10 ± 3 v s 2 2 ± 
4% of in i t ia l synaptic EPSCs, respectively, Mann-Whitney 
test, p = 0.013). These data indicate that perisynaptic 
NMDARs are not saturated under epileptic conditions and are 
capable ofmediating larger EPSC components than in control 
animals when saturated by exogenous D-serine. 
The maximal perisynaptic N M D A EPSCs wi th saturating con­
centrations of exogenous D-serine were larger in epileptic com­
pared wi th control animals (Fig. 5E). This could be attributable to 
an increase in the number of perisynaptic NMDAs or a more 
efficient activation of these receptors by synaptically released glu­
tamate, i.e., via a downregulation of glutamate uptake transport­
ers (Diamond, 2001; Arnth-Jensen et al., 2002). We addressed the 
latter possibility by evaluating the effects of the glutamate uptake 
blocker DL-threo-/3-benzyloxyaspartic acid (TBOA) (30 ju,M)on 
perisynaptic EPSCs. Perisynaptic EPSCs were isolated as de¬
scribed in Figure 5, B and D, w i t h application of MK-801 but 
w i t h saturating concentrations of D-serine present during the 
whole experiment. TBOA caused potentiation of perisynaptic 
EPSCs in both control and pilocarpine-treated animals to the 
same extent (sham. 58.2 ± 9.3%; post-SE, 47.7 ± 14%; exam­
ple traces in Fig. 5F, n = 5 and n = 7 respectively, NS). More¬
over, perisynaptic EPSCs were still significantly larger in 
pilocarpine-treated compared w i t h control animals in the 
presence of TBOA (sham, —17.2 ± 1.2 vs post-SE, —39.3 ± 
2.9 pA, p = 0.0001, ratio of perisynaptic burst EPSC and init ia l 
burst EPSC: sham, 0.15 ± 0.02 vs post-SE, 0.34 ± 0.05, p = 
0.006, Mann-Whitney test). 
These results indicate that a higher densityofextrasynaptic or 
perisynaptic NMDARs is present in epileptic animals. To further 
support this idea, we recorded tonic N M D A currents from gran¬
ule cells by clamping neurons to +40 mV. This allowed us to 
isolate the tonic N M D A current via application of D - A P V in con­
trol versus epileptic rats (Fig. 6). The magnitude of the tonic 
N M D A current proved larger in epileptic compared wi th sham-
controlrats (sham, 26.5 ± 6.3 pA, n = 6; post-SE, 67.0 ± 13.6 pA, 
n = 5, p = 0.018, unpaired t test). 
The small magnitude of perisynaptic N M D A EPSCs in 
control animals precluded an analysis of the contribution of 
different N M D A R subtypes. In epileptic animals, in which 
perisynaptic N M D A EPSCs were larger, we examined the con¬
tr ibut ion of NR2B-containing subunits by applying Ro25-
6981 (0.5 JUM). The experiments were done as in Figure 4, but 
D-serine was included from the onset in all recording solutions. After 
washout of MK-801 and another 5 min baseline recording period, 
Ro25-6981 was applied and caused a reduction of the perisynaptic 
EPSC amplitude by 40 ± 5% (n = 5), a fraction similar to the syn-
aptic NMDARs in epileptic animals. 
Collectively, these data support the notion that extrasynaptic 
or perisynaptic N M D A EPSCs are larger in epileptic animals, 
most likely as a result of an increased density of these receptors. 
Moreover, the coagonist binding site of these receptors seems to 
be unsaturated as evidenced by the facilitating effects of exoge-
nously applied coagonists in epileptic animals. 
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Figure 4. Decreased levels of D-serinecausedesaturation of the allosteric modulatory siteof synaptic NMDARs. A, B, Representative experimentsshowing application of saturating concentrations 
(10 ;utM)ofD-serine after baseline NMDA EPSC recording in sham-control (A) and epileptic (B) rats. Open and filled symbols indicate peak magnitude of NMDA EPSCs elicited with single stimulation 
and burst stimulation, respectively. C, D, Increase in EPSC magnitude with application of D-serine for single stimulations (white bars) and burst stimulation (black bars) in control (C) and epileptic (D) 
animals. E, Summary of the degree of NMDA EPSC potentiation by D-serinefor single and burst stimulation in control and epileptic rats. F, G, Analysis of the charge transfer increase with application 
of D-serinefor single stimulations (white bars) and burst stimulation (black bars) for control (F) and epileptic (G) animals. H, Degree of charge transfer increase by D-serinefor single and burst 
stimulation in control and epileptic rats. /, Long example traces of NMDA EPSCs elicited by burst stimulation before and after D-serine application (black and red traces, respectively). Note the slow 
NMDA EPSC component observed, in particular after D-serine application in epileptic rats. Vertical gray lines indicate the time range at which the slow current was quantified. J, The slow current 
increased significantly both in sham and epileptic rats. K, The fraction of increase was much larger in epileptic animals. Error bars represent SEM. *p < 0.05, * *p < 0.01, < 0.001. 
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Figure 5. The allosteric modulatory site of perisynaptic NMDARs is not fully occupied in epileptictissue. A, B, Time course of a representative experiment designed to analyze perisynaptic NMDARs. A shows 
sample traces of EPSCs in control animals elicited at thetimepointsindicated bythenumbersin B.Baseline EPSCs were recorded using a protocol that isalternatingbetweena single stimulusand burst stimulation 
(5 stimulationsat 100 Hz),applied every 10s. During application of MK-801, single stimulation only was performed to block synaptic NMDARs (B). After washout of MK-801, perisynaptic EPSCs could be elicited 
with the burst stimulation (example traces in A, 2). Application of D-serine (10 MM) did not significantly increasethe burst elicited NMDA EPSCs in control animals (2 and 3 in A and B).Subsequent application of 
D-APV completely blocked the perisynaptic EPSC (4 in A and B). In B, NMDA EPSC amplitudes are normalized to the baseline ofthe burst EPSCs recorded under baseline conditions. C, D, Experiments performed 
as in A and B in epilepticanimals. Notethe significant increase in perisynaptic EPSCs during D-serineapplication visible in C (traces2and 3), D, and the inset of D at larger magnification. E, Changes inamplitudes 
of perisynaptic NMDA EPSCs induced by D-serine in sham and post-SE animals. Data points indicate individual experiments. Application of D-serine induces no significant change of perisynaptic NMDA EPSC 
amplitude in the sham group, whereas NMDA EPSC amplitudes are significantly increased in the post-SE group (*p < 0.05). F, Representative sample traces showing the effect ofthe glutamate transporter 
inhibitor TBOA on perisynaptic NMDAR-mediated EPSCs under saturating glycine-binding site conditions. Blacktraces indicate NMDA EPSCs after stimulation in the presence of MK-801 and in the continuous 
presence of D-serine. Red traces indicate NMDA EPSCs after additional application of TBOA. Application of TBOA increased perisynaptic NMDA EPSCstothe same extent in sham and post-SE groups. 
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Figure 6. Increased tonic NMDA currents in granulecellsfromepilepticanimals.Tonic NMDA 
currents recorded in epileptic animals by clamping neurons to + 40 mV and applying the 
NMDAR blocker D-AP-5. The magnitude of the tonic NMDA current proved larger in epileptic 
compared with sham-control rats. 
Impaired LTP in the epileptic DG is rescued by exogenous 
D-serine 
The results so far indicate that synaptic N M D A R coagonist 
binding sites are less occupied i n epileptic animals, most likely 
as a result of a deficit in D-serine caused by DAO upregulation. 
Because coactivation of the N M D A R coagonist site by glial 
release of D-serine is obligatory in the induction of LTP (Hen-
neberger et al., 2010), we asked whether synaptic plasticity is 
impaired at LPP synapses. In this pathway, tetanic stimulation 
of slices caused stable LTP in control animals (131 ± 6%, n = 
10; Fig. 7A, open symbols, p = 0.005, Wilcoxon's signed-rank 
test vs baseline, LTP success rate of 90%) but failed to elicit 
stable synaptic changes in epileptic animals [102 ± 5%, n = 14 
(filled symbols), p = 0.925, Wilcoxon's signed-rank test vs 
baseline, comparison of LTP levels w i t h control animals, p = 
0.001, unpaired t test; Fig. 7A, see summary in F, LTP success 
rate of 43%]. Similarly, the post-tetanic potentiation was 
strongly reduced in epileptic animals (123 ± 4 v s 1 7 1 ± 9%, 
p = 0.003, unpaired t test). Unlike the LPP, LTP in the MPP 
was not significantly affected (146 ± 10%, n = 14 in 
pilocarpine-treated rats vs 175 ± 17%, n = 13 in control rats, 
p = 0.168; data not shown). I n p u t - o u t p u t curves did not 
reveal any significant differences between control animals 
(n = 7) and animals that had experienced SE (n = 10), in 
either the LPP or MPP (LPP: maximum fEPSP, p = 0.188; 
stimulation intensity required for halfmaximal fEPSP ampli¬
tudes (xhalf), p = 0.483; MPP: maximum fEPSP, p = 0.421; 
xhalf, p = 0.333, unpaired t test ofcurve parameters obtained 
by f i t t ing w i t h a sigmoidal function; data not shown). 
Using an interstimulus interval of 40 ms, the LPP responses ex¬
hibited a typical paired-pulse facilitation (paired-pulse ratio: 136 ± 
4%, n = 24), whereas paired-pulse depression was always observed 
in the MPP (paired-pulse ratio: 84 ± 4%, n = 15). In both portions 
of the perforant path, this form of short-term plasticity remained 
unchanged after SE (paired-pulse ratios of 127 ± 5%, n = 15 and 
88 ± 3%, n = 14 in the LPP and MPP, respectively). As described 
previously (Bushell et al., 1995; Dietrich et al., 1997), the metabo-
tropic glutamate receptor group I I I selective agonist L-AP-4 could be 
used to further discriminate the lateral and medial aspects of the 
perforant path in control animals. L-AP-4 (10 JUM) selectively inhib-
ited LPP-evoked fEPSPs (to 46 ± 5% in LPP, n = 6vs114 ± 8% in 
MPP, n = 5, p < 0.01). Unlike N M D A EPSCs, fEPSPs were insensi-
tive to L-AP-4 after SE (fEPSP amplitude, 101 ± 11% of control in 
LPP vs 117 ± 2% in MPP). One explanation for this discrepancy 
may be that the stronger stimulation incurred with bipolar stimula¬
tion electrodes leads to a pronounced glutamate release in epileptic 
animals that saturates presynaptic mGluRs. In contrast to LTP, 
short-term plasticity of both LPP and MPP synapses during brief 
stimulation trains at various frequencies (10 stimulations at 0.1,1,5, 
10, and 20 Hz) was unaltered (Fig. 7B). Thus, SE causes a long-lasting 
loss of NMDA-dependent long-term, but not short-term, plasticity 
at LPP synapses. 
If loss of LTP is caused by a deficit in D-serine in epileptic hip-
pocampus, addition of exogenous D-serine during LTP induction 
should restore LTP in epileptic rats. Saturating concentrations of 
D-serine (100 JUM) were applied via the bath solution, and equilibra¬
tion was allowed to take place for 1-2 h. LTP levels were strongly 
impaired in pilocarpine animals in the absence of D-serine, as de¬
scribed above, whereas in the presence of D-serine, LTP levels in 
sham and epileptic animals did not seem different (sham, 120 ± 4%, 
n = 14, LTP success rate of 79%; post-SE, 122 ± 7%, n = 13, LTP 
success rate of 77%; Fig. 7C). In the presence of both D-serine and 
low concentrations of the glycine site antagonist CGP78608 ([(1S)-
1-[[(7-Bromo-1,2,3,4-tetrahydro-2,3-dioxo-5-quinoxalinyl)methyl] 
amino]ethyl]phosphonic acid hydrochloride; 0.2 JUM), signifi¬
cant differences between sham and epileptic animals could again 
be observed (Fig. 7D), similar to the native condition. ANOVA 
revealed a significant effect of pilocarpine treatment (F(1,67) = 
17.24, p < 0.0001), no effect of drug treatment ( F ( 2 6 7 ) = 0.33, p = 
0.72), but a significant interaction between these factors (F(2 6 7 ) = 
5.89, p = 0.004). Tukey's post hoc tests to uncover differences 
between individual groups revealed significant differences 
between sham and post-SE groups in the absence of D-serine (p = 
0.005) and in the presence of both D-serine and CGP78608 (p = 
0.003) but not in the presence of D-serine only (p = 0.99, indi-
cated by asterisks in Fig. 7F). This suggests that an action on the 
glycine modulatory site is relevant for the actions ofD-serine. So 
far, these experiments are consistent with the idea that lack of 
D-serine causes a deficient activation of NMDARs during LTP 
induction and that this causes impaired LTP. 
Mechanism ofLTP rescue in epileptic animals 
We next tested which types o f N M D A R s are important for the 
LTP rescue effect in epileptic animals, i.e., in the continued 
presence of 100 uMD-ser ine (Fig. 7G, leftmost bars indicate 
potentiation in the presence of 100 uMD-ser ine for the sake of 
comparison). We applied the selective NR2B antagonist Ro25-
6981 (0.5 JUM), the selective NR2C/D antagonist PPDA (0.3 
u M ) , or the NR2A-preferring blocker NVP-AAM077 (50 n M ; 
Fig. 7G). In sham-control animals, significant potentiation 
versus baseline was obtained, regardless of which N M D A R 
antagonist was present (potentiation of 125 ± 9%, n = 9; 
114 ± 4%, n = 13; and 123 ± 5%, n = 12, respectively; p = 
0.015, 0.019, and 0.002, respectively, Wilcoxon's signed-rank 
test vs baseline). In pilocarpine-treated animals, no significant 
potentiation was observed in the presence of Ro25-6981 (96 ± 
9%, n = 10, p = 0.646) or PPDA (110 ± 13%, n = 9,p = 0.767). 
In the presence of NVP-AAM077, significant potentiation was 
observed (120 ± 5%, n = 7, p = 0.046, Wilcoxon's signed-rank 
test vs baseline). The loss of significant LTP in the presence of 
Ro25-6981 is consistent wi th the relative upregulation of synaptic 
NR2B-containing receptors described in Figure 2. However, it 
should be noted that A N O V A did not reveal significant effects of 
treatment over all compounds tested. 
Impaired spatial memoryafter SE is reversed bydietary 
D-serine 
Although the contribution of different N M D A R subunit com-
binations could not be well resolved, synaptic plasticity in 
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Figure 7. Impaired LTP in the epileptic DG is rescued by exogenous D-serine. A, Tetanic stimulation ofthe LPP with a high-frequency patterned stimulation (HFS) causes stable LTP in control 
animals (open symbols) but not in epileptic animals (filled symbols). B, Short-term plasticity of LPP and MPP synapses during stimulation trains of 10 stimuli at different frequencies. C, LTP at the 
LPP is restored by exogenous D-serine (100 MM). D, Low concentrations of the glycine site antagonist CGP78608 (0.2 MM) cause a reversal ofthe rescue effect without affecting LTP in control animals. 
E, Blocking NR2B-containing NMDARs blocks rescued LTP in epileptic animals. F, Summary of levels of potentiation under native conditions, followed by application of D-serine (D-ser) and after 
combined application of D-serine and CGP78608. Asterisks indicate significant differences in the post hoc Tukey's test. G, Summary ofthe effects of subunit-selective NMDAR blockers on LTP under 
conditions of saturating concentrations ofthe coagonist D-serine, in control and epileptic animals (white and black bars, respectively). * *p < 0.01. 
pilocarpine-treated animals was rescued to the level of control 
animals by D-serine application. Therefore, we tested whether 
D-serine application in epileptic rats is associated w i t h a rescue 
of cognitive dysfunction observed in these animals. We ana¬
lyzed spatial memory in control and pilocarpine-treated rats, 
w i t h and without oral D-serine supplementation (see Materi-
als and Methods). Feeding the rats w i t h 32 mg/kg resulted in 
enhanced hippocampal D-serine content in both control and 
epileptic animals (from 25.6 ± 0.6 to 31.1 ± 0.8% in control 
animals; f rom 22.7 ± 0.4 to 28.0 ± 0.6% in epileptic animals). 
A N O V A revealed a significant effect of chronic epilepsy 
( F(1,30) = 12.3, p = 0.001), as well as a significant effect of 
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Figure 8. Impaired spatial memory after SE is reversed by dietary D-serine. A, The distance moved to reach the platform on the first day (6 consecutive trials) showsa significant working memory 
deficit in post-SE animals compared with sham control. However, there was no treatment effect of D-serine. B, The difference of the average distance traveled during trials 1 and 2 and trials 5 and 
6 was significantly different between sham and epileptic animals during consecutive trials of the first day. This indicates impaired learning in epileptic animals that does not seem to be affected by 
D-serine. C, The average distance traveled during the first trial of each day until reaching the platform, quantified during 7 consecutive days of training. Note the significant deficit in acquiring the 
spatial information in post-SE animals and a significant improvement by oral D-serine supplementation in epileptic rats on days 6 and 7. D, Representative traces of the probe trial on day 8. The 
platform was removed, but for the sake of clarity, the platform position during the days 1-7 is indicated in gray. Data are depicted such that the target quadrant is in the top right corner for all 
animals. E,Averageoccupancy of the target and nontargetquadrantsduring the probe trial. Chance level isat 25% (indicated by red line).Sham-control animalspreferthe target quadrant regardless 
of whether they are treated with D-serine, demonstrating intact spatial memory. The performance of post-SE animals in the probe trial is at chance level, whereas D-serine-treated post-SE animals 
show some recovery of target quadrant preference. *p < 0.05, * *p < 0.01, < 0.001. 
D-serine treatment ( F ( i > 3 0 ) = 28.2, p < 0.0001), w i t h no inter-
action between these two factors. Importantly, the supple-
mentation was able to rescue D-serine levels in epileptic 
animals to a magnitude that was not significantly different 
from control animals. 
Pilocarpine-treated rats displayed a severe learning deficit in the 
Morris water maze. We first tested the acquisition ofplatform posi¬
tion on the first six consecutive trials on the first day of the behavioral 
experiment. In these trials, sham-control animals acquire the plat¬
form location well, whereas epileptic animals perform much worse, 
regardless of whether they were treated with D-serine or not (Fig. 8A, 
open vs filled symbols). The difference between the average distance 
traveled during trials 1 and 2 versus trials 5 and 6 was accordingly 
much larger in sham compared with epileptic animals (ANOVA, 
F(3 3 6 ) = 4.08, p = 0.014, significant effect of pilocarpine treatment, 
F( 1 3 6 ) = 12.0, p = 0.001, no significant effect of D-serine treatment 
and no significant interaction between these factors). Individual 
comparisons with a Tukey's post hoc test revealed significant differ-
ences between the sham versus post-SE groups (p = 0.016) and the 
sham D-serine versus post-SE D-serine groups (p = 0.041, indicated 
by asterisks in Fig. 8B). This indicates a strong deficit in memory 
acquisition during these consecutive trials in epileptic animals that 
does not seem to be affected by D-serine. 
Subsequently, we examined the acquisition of platform posi-
tion on the consecutive7dofthe acquisition period. Although 
sham-control animals invariably showed stable acquisition of the 
platform position (Fig. 8C, open symbols), pilocarpine-treated 
animals were strongly impaired (Fig. 8C, filled circles). D-Serine 
treatment of pilocarpine-treated animals appeared to cause a 
marked improvement in acquisition (Fig. 8C, filled squares). 
When analyzing the average performance on the l a s t 2 d o f t h e 
acquisition period, A N O V A revealed a significant effect of pilo-
carpine treatment CF(^36) = 42.1,p < 0.0001), a significant effect 
of D-serine treatment (F(^ 3 6) = 7.23, p = 0.011), and a significant 
interaction between the two factors CF(^36) = 9.11, p = 0.005). 
Individual comparisons with a Tukey's post hoc test revealed that 
the post-SE group acquired the task significantly worse than 
either sham-control group (p < 0.0001) and that D-serine 
treatment significantly improved performance in epileptic an-
imals (post-SE vs post-SE D-serine, p < 0.001). We then per¬
formed a probe trial in the absence ofthe platform on the day 
immediately after the 7 d acquisition period (Fig. 8D). Sham-
control animals showed stable retention of the platform posi¬
t ion , evidenced by a preferential occupancy of the target 
quadrant. Epileptic animals without D-serine treatment 
searched equally in target and nontarget quadrant. D-Serine 
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application in epileptic animals appeared to reconstitute pref¬
erence of the target quadrant (Fig. 8E). A N O V A revealed a 
significant effect of pilocarpine treatment (F ( 1 3 6 ) = 5.44, p = 
0.025) b u t n o t of D-serine treatment (F ( 1 3 6 ) = 2,22, p = 0.145) 
and no interaction between these two factors. 
Epileptic rats showed a significantlyhigherswimmingvelocity 
compared wi th control animals, whereas there was no significant 
effect of treatment with D-serine (post-SE, 23.4 ± 0.2 cm/s; 
post-SE D-serine, 23.3 ± 0.3 cm/s; sham, 21.1 ± 0.5 cm/s; sham 
D-serine, 20.4 ± 0.3 cm/s; ANOVA on ranks; Tukey's post hoc 
test: post-SE vs sham, p < 0.05; post-SE D-serine vs post-SE, p > 
0.05; sham D-serine vs sham, p > 0.05). We also analyzed thig-
motaxis by determining the fraction of time spent close to the r im 
(within 10 cm). Epileptic rats showed significantly higher thig-
motaxis compared with control animals (post-SE, 58.5 ± 3.6%; 
post-SE D-serine, 50.3 ± 4.0%; sham, 28.1 ± 3.1%; sham 
D-serine, 28.3 ± 4.0%; ANOVA, Holm-Sidak post hoc test: 
post-SE vs sham, p < 0.001; post-SE D-serine vs post-SE, p = 
0.133; sham D-serine vs sham, p = 0.965), but there was no sig¬
nificant effect of D-serine on thigmotaxis in both experimental 
groups. This suggests that the D-serine treatment effects seen in 
memory acquisition are not likely to be caused by changes in 
motor function or altered thigmotaxis. 
Effects on seizure frequency after dietary D-
serine administration 
These results demonstrate that epileptic animals show a severe 
spatial learning deficit. Furthermore, reconstituting CNS 
D-serine levels significantly reversed deficits in the acquisition of 
spatial memories. Together, these results suggest that reversing 
deficient N M D A R function and synaptic plasticity with exoge¬
nous D-serine leads to improvement in cognitive deficits associ¬
ated w i t h chronic epilepsy. However, increasing N M D A R 
function in the epileptic brain might also have unwanted effects, 
for instance, an increase in seizure frequency. Therefore, we exam¬
ined seizure frequencies by video monitoring in epileptic animals 
receiving dietary D-serine and compared them with epileptic animals 
without D-serine supplementation (see Materials and Methods). 
These experiments revealed average seizure frequencies of0.6 ± 0.2 
versus 0.9 ± 0.2 generalized stage 4/5 seizures per day in animals 
without and with D-serine treatment, respectively ( p = 0.43, un¬
paired t test, n = 15 for both groups). Likewise, the severity of the 
seizures when classified as described in Materials and Methods was 
not significantly different (average severity score, 2.6 ± 0.7and3.5 ± 
0.9, p = 0.30, Mann-Whitney test). 
Discussion 
NMDARs are central for induction of most forms of synaptic 
long-term plasticity and for learning and memory. The activation 
of the N M D A R complex and the resulting synaptic plasticity re¬
quires not only binding of the neurotransmitter glutamate but 
also occupancy of a coagonist binding site on the NR1 subunit 
(Schell et al., 1995; Mothet et al., 2000; Panatier et al., 2006; 
Henneberger et al., 2010). In this study, we showmarked changes 
in excitatory synaptic transmission in epilepsy. First, we show a 
change in N M D A R subunit composition, wi th synaptic NR2B-
containing receptors being more prevalent in epileptic neurons. 
Second, we show that levels of the endogenous N M D A R co-
agonist D-serine are strongly reduced in the epileptic brain. 
This leads to desaturation of synaptic NMDARs, causing a 
reduction in synaptic N M D A currents. The modulatory site of 
perisynaptic receptors is also desaturated, w i t h a compensa-
tory increase in the number of perisynaptic NMDARs. Finally, 
we demonstrate that the deficit in NMDAR-dependent synap-
tic transmission is associated w i t h deficient synaptic long-
term plasticity and that plasticity as well as learning and 
memory are reinstated by exogenous application of the coago-
nist D-serine in vitro and in vivo. 
Changes in D-serine mediated cotransmission in epilepsy 
D-Serine is considered to be the predominant physiological l i -
gand of the N M D A R coagonist site in forebrain regions (Panatier 
et al., 2006) and has been shown to be more effective in potenti-
ating the N M D A R than glycine (Matsui etal., 1995; Stevens et al., 
2010). Our data suggest that the coagonist binding sites of syn-
aptic NMDARs in the hippocampus are not saturated, consistent 
wi th previous studies (Yang et al., 2003; Junjaud et al., 2006; 
Henneberger et al., 2010). Our results further suggest that epi-
lepsy results in a significant decrease of D-serine, which is associ-
ated with a desaturation of the coagonist binding site of synaptic 
and extrasynaptic NMDARs. We found that the mRNA expres¬
sion of the D-serine synthesizing enzyme serine racemase is 
decreased in the CA1 region, wi th a concomitant significant de¬
crease in hippocampal protein levels. This finding is similar to the 
changes observed in the aging brain, in which decreased D-serine 
content, desaturation of NMDARs, and impaired LTP were 
linked to an decreased expression of serine racemase (Junjaud et 
al., 2006; Mothet et al., 2006). In addition, we found a significant 
increase in the expression of the D-serine degrading enzyme DAO 
from very low levels normally present in forebrain but were un¬
able to verify this finding with Western blot analyses because of 
the still very low levels of this protein. Thus, although DAO could 
contribute to decreased D-serine content, the significance of this 
finding is unclear. These mechanisms do not exclude the contri¬
bution of additional mechanisms. For instance, protein kinase C 
regulates D-serine availability (Vargas-Lopes et al., 2011), and the 
expression ofPKC isoforms is upregulated in some epilepsymod-
els (Guglielmetti et al., 1997). EphrinB powerfully regulates 
D-serine synthesis and release in astrocytes, but how this mole¬
cule is regulated in epilepsy is not known (Zhuang et al., 2010). 
Mechanism of D-serine-mediated restoration of 
synaptic plasticity 
We found that supplying exogenous D-serine to compensate for 
the loss of endogenous D-serine was sufficient to restore impaired 
LTP in the epileptic DG. We have shown that D-serine application 
is sufficient to rescue impaired LTP at the LPP to dentate granule 
cell (DGC) synapse. What is the mechanism of this rescue? Our 
data show that saturating D-serine concentrations caused a po-
tentiation of synaptic NMDARs but also in particular perisynap-
tic N M D A EPSCs in chronic epilepsy. Our experiments cannot 
discriminate whether the D-serine action on synaptic or peri-
synaptic sites is more important in the rescue phenomenon. 
Most likely, both are involved. For instance, perisynaptically 
located NMDARs have been shown to be involved in the in¬
duction of LTP (Harney et al., 2008). Furthermore, Hen-
neberger et al. (2010) showed that LTP induction at the 
Schaffer collateral to CA1 synapse depends on D-serine release 
from astrocytes. It is likely that this reflects, at least in part, 
activation of extrasynaptic NMDARs by astrocytic glutamate. 
An intriguing corollary of our f inding is that, at least in the 
DG, downstream signaling cascades for the expression ofLTP 
seem to be intact, suggesting that substitution of exogenous 
D-serine might indeed be a successful strategy to restitute de¬
ficient LTP and cognition in vivo. 
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Changes in NMDAR subunit composition 
A changed N M D A R subunit composition was observed at the 
LPP to DGC in chronic epilepsy. Although functional expression 
of NR2B-containing receptors was significantly increased, func-
tional expression of NR2C/D-containing receptors was reduced. 
This change in subunit composition was associated wi th signifi¬
cantly slower N M D A EPSC kinetics, consistent wi th the slower 
kinetics of NR2B-containing receptors (Erreger et al., 2005; 
Rauner and Kohr, 2011). Increases in NR2B expression have been 
observed in various forms of epilepsy models, as well as human 
epilepsy. An increased NR2B expression in dysplastic human neo-
cortex was correlated with the expression of in situ epileptogenesis in 
human cortical dysplasia, which is often associated with pharmaco-
resistant epilepsy (Moddel et al., 2005). Furthermore, a recent study 
of short-term effects of pilocarpine in primary cultures of hip-
pocampal neurons showed an increased expression of NR2B sub-
units (Sun et al., 2009; Di Maio et al., 2011, Muller et al., 2013; but see 
Auzmendi et al., 2009). Our findings rely on the use of subunit-
specific antagonists and therefore are contingent on their specificity. 
Based on I C 5 0 values for NR2B, the selectivity of Ro25-6981 for 
NR2B- over NR2A-containing NMDARs is considered to be 
~5000-fold (Fischer et al., 1997) and was used in very low concen-
trations (0.5 JUM) to further ensure specificity. The NR2A-selective 
antagonist NVP-AAM077 is 100-fold selective for NR2A- over 
NR2B-containing receptors (Auberson et al., 2002) at low concen¬
trations equivalent to those used in this study (Feng et al., 2004) and 
has been used extensively to characterize native NR2A subunit func-
tion (Liu et al., 2004; Berberich et al., 2005). It should be noted that 
the NR2C/D-selective antagonist PPDA at the concentration range 
used is less selective, with a threefold to sixfold higher affinity for 
NR1A/NR2D receptors compared with NR1/NR2A or NR1/NR2B 
(Feng et al., 2004). Nevertheless, this compound has also been used 
to pharmacologically dissect the role of NR2D-containing receptors 
in synaptic plasticity (Hrabetova et al., 2000; Harney et al., 2008). 
D-Serine and novel therapies in epilepsy 
Our results suggest that exogenous D-serine cannot only restitute 
NMDAR function and synaptic plasticity but can also improve cog¬
nitive function in epileptic animals. Indeed, evidence is accumulat¬
ing that D-serine might be useful in treating cognitive dysfunction. 
D-Serine improves performance in recognition memory and work-
ing memory tasks in mice (Bado et al., 2011), as well as social mem-
ory in rats (Shimazaki et al., 2010). In schizophrenia, a reduction in 
NMDARfunction mayaccount for a substantial portion ofthe dys¬
function seen in this disorder (Coyle, 2006). Blocking NMDARs 
(Krystal et al., 2002) or genetically reducing NMDAR function in 
interneurons causes schizophrenia-like symptoms (Belforte et al., 
2010). Interestingly, D-serine was found to improve positive, nega-
tive, and cognitive symptoms in patients with schizophrenia (Tsai et 
al., 1998, 1999). Collectively, this suggests that augmenting 
NMDA-mediated transmission through the N M D A coagonist 
binding site is promising for the pharmacotherapyofschizophre-
nia but perhaps also of epilepsy. One advantage of D-serine may 
be the allosteric nature of N M D A R augmentation, as well as the 
fact that it affects no other known neurotransmitter system, in¬
cluding the strychnine-sensitive inhibitory glycine receptor. An 
alternate strategy to increase D-serine levels has been the devel¬
opment of DAO inhibitors for the treatment of schizophrenia, 
which are currently being examined for clinical efficacy (Smith et 
al., 2009, 2010). Because DAO expression was elevated in the DG 
in chronic epilepsy, at least on the mRNA level, such compounds 
might be candidates for treating disturbed cognition in chronic 
epilepsy. DAO inhibitors might be safer than D-serine, because 
DAO catabolism of high doses of D-serine can have cytotoxic 
effects in astrocytes (Park et al., 2006; Chung et al., 2010). The fact 
that disturbed metabolism of D-serine is a feature of both epilepsy 
and psychosis and that D-serine treatment alleviates symptoms in 
both disorders is also intriguing in view of the fact that there is a 
clinical comorbidity of both disorders (Johnson and Shorvon, 
2011; Clarke et al., 2012; Hesdorffer et al., 2012). 
One critical question in using D-serine as a treatment option 
in epilepsy is whether the increase in N M D A R function that ben¬
efits cognition might cause increased seizures attributable to aug¬
mented NMDAR-dependent excitation. We found no significant 
effect on seizure frequencies measured by video monitoring in 
epileptic animals receiving dietary D-serine. It should be noted 
that video monitoring may not detect all partial seizures and that 
a definitive determination of partial seizure frequencies would 
require long-term telemetric analysis. Nevertheless, these results 
indicate that there are no deleterious effects of D-serine on gen¬
eralized seizure frequency. 
Together, our results have uncovered a deficiency in 
D-serine as a cause for deficient N M D A R activation and syn-
aptic plasticity, as well as cognitive function in chronic epi¬
lepsy, and suggest novel avenues to treat cognitive dysfunction 
in epilepsy patients. 
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